Wire · opportunities
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 November 2026 · Fusion42 review
Merck and Kelun-Biotech's antibody drug conjugate sacituzumab tirumotecan (sac-TMT) significantly improved overall survival in a Phase 3 trial for advanced gastroesophageal cancer, marking a key regulatory milestone and expanding its potential global market. Despite missing secondary endpoints, sac-TMT advances Merck's wider TroFuse program targeting multiple cancers and aligns with their plans for regulatory submissions.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You need to pivot towards therapies improving overall survival for tough cancers as sac-TMT's FDA priority review shows regulators now favour OS data over secondary endpoints. Your development plans must reflect this if you want to clear regulatory hurdles and expand market access.
◆ Coverage
2 sources · 20 Nov 2026
◆ Related on Wire
◆ Topics